The Oligonucleotide Therapeutics Society Presents the 2021 Virtual Conference
September 04, 2021 11:00 ET | Oligonucleotide Therapeutics Society
SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics. While...
Olix Logo.jpg
OliX Pharmaceuticals Announces Results from Preclinical Study of NASH Therapeutic Candidate
August 04, 2021 09:00 ET | OliX Pharmaceuticals
- OLX702A reversed liver tissue damage in mouse model of NASH - Results and additional pipeline updates across hair loss, AMD and HBV programs presented at 48th KAST International Symposium -...
22157.jpg
Global Antisense & RNAi Therapeutics Market Report 2021: Market is Expected to Reach $1.79 Billion in 2025 at a CAGR of 11% - Forecast to 2030
June 17, 2021 07:03 ET | Research and Markets
Dublin, June 17, 2021 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...
Olix Logo.jpg
OliX Pharmaceuticals to Present at 2021 RNAi-Based Therapeutics Summit
June 14, 2021 10:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, June 14, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that June Hyun Park, Ph.D.,...
Olix Logo.jpg
OliX Pharmaceuticals to Conduct One-on-One Meetings with Potential Partners at BIO Digital 2021 Conference
June 10, 2021 15:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, June 10, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
Olix Logo.jpg
OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Androgenic Alopecia
June 09, 2021 10:00 ET | OliX Pharmaceuticals
SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and LGC, a global leader in the life...
22157.jpg
Global $105+ Billion Agricultural Biotechnology Markets, 2020-2021 & 2030
June 04, 2021 06:28 ET | Research and Markets
Dublin, June 04, 2021 (GLOBE NEWSWIRE) -- The "Agricultural Biotechnology Market Research Report: By Technology (Genome Editing, DNA Sequencing, RNAi, Synthetic Biology, Biochip), Product...
Olix Logo.jpg
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics
May 24, 2021 08:00 ET | OliX Pharmaceuticals
SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of...
22157.jpg
Global Oligonucleotide Synthesis Markets Report 2021-2026 - Increasing Use of Synthesized Oligos in Therapeutic Applications with Growing Focus on Personalized Medicine
May 20, 2021 04:38 ET | Research and Markets
Dublin, May 20, 2021 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic...
Capture.PNG
Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases
April 28, 2021 07:00 ET | Silence Therapeutics plc
Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases 28 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq:...